Dr. Alexandre Mark Tungesvik, MD

Dr. Tungesvik practices at Fitzgibbon Hospital in Marshall, Missouri, part of American Medical Administrators.

Dr. Tungesvik's NPI, 1538691381, was assigned on March 31, 2017. Dr. Tungesvik graduated from University of Missouri, Columbia School of Medicine in 2017. Dr. Tungesvik holds Missouri license 2023011840.

Dr. Tungesvik's primary practice is Fitzgibbon Hospital, at 2305 S 65 Highway, Marshall, MO 65340 in Saline County. The practice phone is (660) 886-7431.

Dr. Tungesvik's primary practice is Fitzgibbon Hospital in Marshall, Missouri, part of American Medical Administrators. Dr. Tungesvik is also affiliated with University Hospital. The medical group on file is Missouri Cancer Associates. Dmand AI also links Dr. Tungesvik to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tungesvik practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tungesvik's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tungesvik is licensed in Missouri.

CMS data shows 147,940 Medicare services from Dr. Tungesvik across 67 procedure codes in 2024, for 919 Medicare patients. Medicare paid $2,733,831 for them.

CMS counts 919 Medicare patients who saw Dr. Tungesvik in 2024. The largest group is 65 to 74, with 406 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tungesvik's median patient age at 71, with 60% women.

In 2024, Dr. Tungesvik wrote 1,395 Medicare Part D claims for 278 patients. 86% of them were for generic drugs. CMS names the drug for 1,134 of them, across 35 drugs with 11 or more claims each, at $742,351 in total drug cost. In 2023, CMS named 227 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Tungesvik for performance year 2024. Dr. Tungesvik accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Tungesvik, published from 2020 to 2021. 2021 was the busiest year, with 2. The most frequent topics are Multiple Myeloma and Antineoplastic Agents. Dr. Tungesvik's most frequent co-authors are Kenneth H. Shain, MD, Rachid C. Baz, MD and Jason B. Brayer, MD, PhD.

CMS Open Payments shows 274 general payments to Dr. Tungesvik from 36 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 95% of the total. Bristol-Myers Squibb Company paid the most, $745.

Dr. Tungesvik graduated from University of Missouri, Columbia School of Medicine in 2017.